An open-label, randomized, prospective study to investigate the safety and efficacy of Campath-1H as an induction agent in combination with tacrolimus monotherapy compared to short-course ATG [antithymocyte globulin]-induction in combination with tacrolimus, mycophenolate mofetil and short-term steroids application in de novo SPK [simultaneous pancreas-kidney transplant] transplanted diabetic patients

Trial Profile

An open-label, randomized, prospective study to investigate the safety and efficacy of Campath-1H as an induction agent in combination with tacrolimus monotherapy compared to short-course ATG [antithymocyte globulin]-induction in combination with tacrolimus, mycophenolate mofetil and short-term steroids application in de novo SPK [simultaneous pancreas-kidney transplant] transplanted diabetic patients

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2012

At a glance

  • Drugs Alemtuzumab (Primary) ; Antithymocyte globulin (Primary) ; Methylprednisolone; Mycophenolate mofetil; Prednisolone; Tacrolimus
  • Indications Kidney-pancreas transplant rejection
  • Focus Therapeutic Use
  • Acronyms SIMPATICO
  • Most Recent Events

    • 19 Jul 2012 Results presented at the 24th International Congress of the Transplantation Society.
    • 18 Jun 2012 Actual patient number is 30 according to ClinicalTrials.gov.
    • 18 Jun 2012 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top